Doctors and groups representing employers said they’re increasingly hearing about companies cutting weight loss drugs out of ...

Emil Kongshøj Larsen, Executive Vice President for International Operations at Novo Nordisk, talks to BT about India’s role ...

Eli Lilly ( LLY 1.19%) and Novo Nordisk ( NVO 2.44%) are two of the leading companies in the fast-growing GLP-1 weight loss ...

Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada ...

Brace yourselves, Ozempic and Zepound. Eli Lilly just released a jaw-dropping sneak peek from the final phases of testing for ...

The City of Huntsville has taken another step toward bringing pharmaceutical giant Eli Lilly’s $6 billion facility to the ...

Eli Lilly and Company has delivered significant positive developments this week, though its shares experienced a minor pullback in Wednesday's trading sessio ...

Though it hasn't even wrapped up clinical trials, the weight loss drug retatrutide already has a cult following.

Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal ...

The new "triple agonist" weight loss medication called retatrutide can help people lose an average of 28.7 percent of ...

In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...